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Abstract
AIM: To determine whether there are gender differ-
ences in the epidemiological profile of atrial fibrillation 
(AF) and to characterise the clinical, biochemical, and 
therapeutic factors associated with AF.
METHODS: Each investigator (primary care physicians 
or physicians based in hospital units for hypertension 
treatment) recruited the first 3 patients with an age 
of ≥ 65 years and a clinical diagnosis of hypertension 
(ambulatory blood pressure monitoring and an elec-
trocardiogram, were performed) on the first working 
day of the week for 5 wk and identified those individu-
als with atrial fibrillation. A binary logistic regression 
was performed, including all of the variables that were 
significant in the univariate analysis, to establish the 
variables that were associated with the presence of ar-
rhythmia. 
RESULTS: A total of 1028 patients were included in the 
study, with a mean age of 72.8 ± 5.8 years. Of these 
patients, 47.3% were male, 9% were smokers, 27.6% 
were diabetics, 48.3% had dyslipidaemia, 10.9% had 
angina, and 6.5% had experienced a myocardial infarc-
tion. Regarding gender differences, the men exhibited 
a larger waist circumference, a lower body mass index, 
less obesity, and a more extensive history of diabetes, 
smoking, ischaemic heart disease, kidney failure, pe-
ripheral arterial disease and carotid disease than the 
women. There were no differences, however, in the 
prevalence of AF between the men and the women 
(11.5% vs  9.2%, respectively; P  = no significant). Re-
garding treatment, the women received antiplatelet 
agents and diuretics less frequently, but there were no 
other differences in the use of antihypertensive and an-
tithrombotic therapies. In the multivariate analysis, AF 
in the total study population was associated with age, 
alcohol consumption, the presence of heart disease, 
and decreased glomerular filtration. In the women, AF 
was associated with all of the factors included in the 
overall analysis, as well as the presence of left ventricle 
hypertrophy. In contrast, in the men, the only risk fac-
tors associated with AF were age, the presence of heart 
disease and alcohol consumption.
CONCLUSION: In patients with hypertension over 65 years 
of age, there are relevant gender differences in the factors 
associated with AF.
© 2013 Baishideng. All rights reserved.
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Core tip: The presence of atrial fibrillation (AF) in hy-
pertensive patients with an age of ≥ 65 years was as-
sociated with age, alcohol consumption, the presence 
of heart disease, and decreased glomerular filtration. 
In women, AF was associated with all of the factors 
included in the overall analysis, as well as the presence 
of left ventricle hypertrophy, whereas in men, the only 
risk factors associated with AF were age, the presence 
of heart disease and alcohol consumption. Thus, in pa-
tients with hypertension who are over 65 years of age, 
there are relevant gender differences in the factors as-
sociated with AF.
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INTRODUCTION
Although cardiovascular disease (CVD) has historically 
been considered to affect mainly men, we now know that 
CVD is the main cause of  death in both men and women 
worldwide[1]. However, a number of  occasionally signifi-
cant gender differences can be observed in the morbidity, 
mortality, risk-factor profiles, and clinical presentation of  
CVD. These differences are consistent between all of  the 
populations and regions analysed and are thus relevant to 
the development of  programmes for the prevention and 
treatment of  CVD.
The INTERHEART study found that, on average, 
women experience their first myocardial infarction 9 years 
later than men[2]. Similarly, a recent review reported that 
men experience their first stroke 4.3 years before women, 
on average[3]. However, as the prevalence of  atrial fibrilla-
tion (AF) has increased in recent years due to the ageing 
of  the population, the longer survival of  patients with 
heart disease and, of  course, more frequent diagnosis, 
among other factors, AF has become a major public 
health problem, particularly due to the associated risk of  
stroke and mortality[4]. Women are not exempt from this 
disease, as in addition to presenting several cardiovascular 
risk factors, their life expectancy is longer. The incidence 
in women is thus not negligible, and the probability of  
complications, and particularly cerebrovascular problems, 
is relatively high. This phenomenon is likely due to the 
prevalence of  hypertension in women, which is the most 
important risk factor for both AF and stroke. 
The purpose of  this sub-study is to establish whether 
there are any gender-related epidemiological, clinical, bio-
chemical, or therapeutic differences or differences in the 
factors associated with AF in hypertensive patients over 
65 years of  age.
MATERIALS AND METHODS
The FAPRES registry is a healthcare, teaching and re-
search project sponsored by the Valencian Society of  
Hypertension and Vascular Risk and supported by the 
Spanish Society of  Hypertension-Spanish League for the 
Fight Against Hypertension (SEH-LELHA). The current 
study was designed to establish the prevalence of  AF in 
patients of  ≥ 65 years of  age with a clinical diagnosis of  
hypertension (HT) in the region of  Valencia, Spain. This 
study involved the participation of  69 primary care physi-
cians and physicians based in HT hospital units, a pro-
portion similar to the population census of  each of  the 
three provinces. Written informed consent was obtained 
from all of  the patients, and the study was performed 
following the principles of  the Declaration of  Helsinki 
(Edinburgh Amendment, 2000) and after approval by a 
hospital ethics committee (Clinical Research Ethics Com-
mittee of  the Hospital General Universitario of  Castel-
lon). The general study methods and the determination 
of  the sample size were described in previous publica-
tions[5,6]. This study is a subanalysis of  these data, focus-
ing on differential issues based on gender. 
Patients
Each investigator recruited the first three patients who 
attended the outpatient clinic on the first working day of  
the week for 5 wk during the recruitment period and who 
met all of  the inclusion criteria and none of  the exclusion 
criteria. The inclusion criteria were as follows: (1) over 
65 years of  age; (2) a previous diagnosis of  HT, at least 3 
mo before the start of  the study, according to the Good 
Clinical Practice (GCP) guidelines[7]; and (3) consent to 
participate in the study. The exclusion criteria were an 
arm circumference greater than 42 cm, the presence of  
conditions ineligible for the study or for performing am-
bulatory blood pressure monitoring (ABPM), and the in-
ability to understand and sign the consent form.
Clinical blood pressure (BP) measurement was per-
formed following the GCP recommendations[8,9], using 
a validated automatic electronic device. The patient was 
considered to have good HT control when the mean sys-
tolic BP (SBP) and diastolic BP (DBP), based on the two 
measurements obtained at the visit, were below 140 and 
90 mmHg, respectively.
The 24-h ABPM was performed using SpaceLabs 
90207 devices (SpaceLabs, Inc. Richmond, WA, United 
States) specifically supplied for the project. The monitors 
were scheduled to perform a BP measurement every 20 
min during the activity period and every 30 min during 
the night rest period. Each period was defined individu-
ally in each registry according to the bedtime and wake-
up time reported by the patient. Registries not meeting 
the pre-established quality standards were excluded[10]. 
According to the guidelines of  the European Societies 
of  Cardiology and Hypertension (ESH/ESC)[8], a good 
ambulatory control was defined as having BP values of  < 
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130/80 mmHg (SBP/DBP) in a 24-h period.
Variables
The variables collected via clinical interview were age; 
gender; weight; height; body mass index (BMI) (obesity 
was defined when this parameter was ≥ 30 kg/m2); waist 
circumference (abdominal obesity was defined when 
this parameter was ≥ 102 cm in men or ≥ 88 cm in 
women)[11]; time from the onset of  HT; excessive alcohol 
intake (over 30 g/d)[12]; and known cardiovascular risk 
factors (CVRFs), such as smoking, diabetes, dyslipidae-
mia (total cholesterol > 250 mg/dL, low-density lipopro-
tein (LDL)-cholesterol > 155 mg/dL, high-density lipo-
protein (HDL)-cholesterol < 40 mg/dL in men or < 48 
mg/dL in women, or receiving lipid-lowering treatment), 
and a family history of  early cardiovascular disease (< 55 
years of  age in men or < 65 years of  age in women).
All of  the patients underwent an electrocardiogram 
that was sent by regular mail to a reference centre, where 
two expert cardiologists who were not familiar with the 
patients’ clinical data analysed the heart rhythm inde-
pendently. In the case of  a disagreement between the 
experts, another specialist was asked to participate. Data 
on lesions in the target organs and associated clinical 
conditions were also collected, as follows: the presence or 
absence of  left ventricular hypertrophy (Sokolow or Cor-
nell electrocardiographic criteria), renal damage (increased 
serum creatinine from 1.3-1.5 mg/dL in men or 1.2-1.4 
mg/dL in women), microalbuminuria, an albumin/cre-
atinine ratio of  22-300 mg/g in men or 31-300 mg/g in 
women or albuminuria of  30-300 mg/24 h, and a glo-
merular filtration rate (GFR) estimated from the serum 
creatinine values according to the abbreviated formula 
from the Modification of  Diet in Renal Disease study[13] 
(renal disease was defined for a GFR of  < 60 mL/h peer 
m2). Further data were collected on carotid disease (when 
the patient was diagnosed with an intima-media thickness 
> 0.9 mm or plaque) and previous heart disease (defined 
as the presence of  ischaemic heart disease, heart fail-
ure or both). Additionally, we recorded the presence of  
previous cerebrovascular disease and peripheral arterial 
disease. The class and number of  therapeutic subgroups 
of  antihypertensives used for the treatment of  HT were 
also recorded. AF was defined as having a history of  
arrhythmia beginning at least 3 mo before the study, as 
determined by medical records), even if  the patients were 
now experiencing sinus rhythm or were diagnosed by the 
ECG performed on all of  the patients.
An external audit of  10% of  the questionnaires was 
performed randomly to verify the reliability of  the data 
included in the study. 
Statistical analysis
The results were expressed as frequencies and percentag-
es for the qualitative variables and as averages with stan-
dard deviations for the quantitative variables. The 95%CI 
was calculated for the variables of  interest assuming nor-
mality using a Kolmogorov-Smirnov test. For the com-
parison of  means, a Student’s t test for independent data 
was used; when comparing quantitative data not follow-
ing a normal distribution, the nonparametric Mann-Whit-
ney test was used; and for the possible association be-
tween qualitative variables, the χ 2 test was implemented, 
establishing statistical significance at P < 0.05. Finally, to 
establish the variables that were associated with the pres-
ence of  AF, a binary logistic regression was performed 
that included all of  the variables that were significant in 
the univariate analysis. The presence of  confounding fac-
tors was evaluated by the analysis of  interactions. The 
calibration of  the multivariate model was tested using the 
Hosmer-Lemeshow statistic and the discriminative power 
using the area under the receiver operating characteristic 
(ROC) curve obtained by analysing the probability of  the 
prognosticated value of  the multivariate model. A general 
analysis and an analysis for each gender were conducted. 
All of  the analyses were performed using the SPSS sta-
tistical package, version 15.0 (SPSS Inc., Chicago, Illinois, 
United States).
RESULTS
During the period from June to December 2008, 1028 
patient records were included in this study, 954 of  which 
(92.8%) met the pre-established quality standards for 
evaluation (lacking incomplete data and protocol devia-
tions, for example)[10]. The mean age of  the patients was 
72.8 ± 5.8 years, and 486 (47.3%) were men, 48.3% had 
dyslipidaemia, 27.6% were diagnosed with diabetes mel-
litus, 36.2% performed physical exercise at least twice a 
week, 3.7% reported regular alcohol intake, 10.9% had 
a history of  angina, 6.5% presented with myocardial in-
farction, and 5% experienced coronary revascularisation. 
Other associated diseases were heart failure in 7.3% of  
patients, stroke in 7.5%, and renal failure in 6.1%. Of  the 
patients included in the study, 37.4% were obese based on 
BMI, and 75.8% were obese based on waist circumfer-
ence. The prevalence of  AF was 10.3% (9.2% in women 
and 11.5% in men), with 6.7% evidencing AF when an 
electrocardiogram (ECG), was performed and the other 
3.6% having a history of  AF, but at the time of  analysis, 
experiencing sinus rhythm. Additionally, 1.7% of  patients 
had no history of  AF but were currently experiencing this 
arrhythmia. The laboratory, electrocardiographic and treat-
ment data are included in Table 1.
BP control and treatment in the study population
The mean duration of  HT in the overall sample was 10.9 
± 8.2 years, and 35.3% of  the patients were treated ac-
cording to the BP measured at the clinic, whereas 50.9% 
were treated according to the BP determined by ABPM. 
The mean BP measured at the clinic was 146.7/81.1 
mmHg and determined by ABPM was 128.5/70.8 
mmHg. Only 6% of  the patients were not being treated 
with antihypertensive drugs, 35.6% were taking a single 
drug, 35.6% were taking two, and 22.7% were taking 
three or more.
126 May 26, 2013|Volume 5|Issue 5|WJC|www.wjgnet.com
Fácila L et al . Gender differences
127 May 26, 2013|Volume 5|Issue 5|WJC|www.wjgnet.com
GFR.
AF-related risk factors 
No significant interactions were determined between 
gender and other clinical features in AF patients (Table 3). 
However, the presence of  AF in the total study popula-
tion was associated with age, with a 10% increase in AF 
prevalence per year; alcohol intake; previous heart dis-
ease; and GFR reduction.
In the gender-specific multivariate analysis, the pres-
ence of  AF in the women was related to all of  the overall 
analysis factors, in addition to the presence of  strain in 
the ECGs (associated with LVH). In contrast, there was 
no association between AF and regular alcohol intake. 
In the men, unlike in the women, AF was only associ-
ated with age, the presence of  heart disease (ischaemic 
or heart failure or both), and regular alcohol intake. The 
multivariate analysis was accurately calibrated [P = no sig-
nificant (NS) and χ 2 = 16.5] and had discriminative power 
(for the total study population, an area under the curve 
of  0.78, 95%CI: 0.74-0.83, and P < 0.01; for the analy-
sis of  the men only, an area of  under the curve of  0.75, 
Gender differences 
Table 2 shows the differences between the men and the 
women in epidemiological, biochemical, BP and thera-
peutic characteristics. The women exhibited more obe-
sity, greater sedentariness, a higher systolic and diastolic 
BP in the first clinic measurement, a higher heart rate, a 
higher percentage of  BP control during ABPM (55.7% 
in women vs 45.7% in men, P < 0.001), and higher HDL-
cholesterol values (56.1 ± 13.5 in women vs 49.4 ± 15.1 
in men, P < 0.001). In addition, the women had a higher 
percentage of  LVH, as determined by ECG (Cornell 
voltage criterion), and more frequently used diuretics 
than the men. In contrast, the men exhibited a greater 
abdominal circumference and a higher prevalence of  a 
history of  diabetes, active smoking, alcohol consumption, 
ischaemic heart disease, peripheral arterial disease, renal 
disease, and carotid disease. Regarding the control of  BP 
at the clinic, this parameter was higher in the men (39.9% 
in men vs 31.2% in women, P = 0.004), who also had 
higher uric acid values and more frequently used anti-
aggregation drugs. There were no differences in the pres-
ence of  AF; the use of  other antihypertensive treatments, 
such as beta-blockers, ARA-2, and ACEIs; or other bio-
chemical data, including blood sugar, total cholesterol, 
LDL-cholesterol, triglycerides and creatinine levels and 
Table 1  Baseline characteristics of the study population, 
including biochemical, electrocardiogram and treatment data 
(mean ± SD)  n  (%)
Characteristics Data
WBC, mm3    6727 ± 1774
Haemoglobin, g/dL  13.6 ± 1.8
Glucose, mg/dL  108 ± 31
LDL-cholesterol, mg/dL  118 ± 34
Triglycerides, mg/dL  129 ± 73
Uric acid, mg/dL    5.2 ± 1.1
Creatinine, mg/dL    0.97 ± 0.28
Glomerular filtration rate, mL/min       75 ± 22.5
Albumin/creatinine ratio      39.4 ± 109.8
Heart rate, bpm 71.7 ± 14
Normal QRS     794 (77.2)
Q waves     25 (2.4)
Sokolow LVH     15 (1.5)
Cornell LVH  103 (10)
Strain     84 (8.2)
Global LVH     177 (17.2)
Measurement of anti-HT  1.7 ± 0.87
Diuretics     535 (52.1)
Beta-blockers     240 (23.4)
Calcium antagonists    199 (19.4)
ACEI     265 (25.8)
ARB     611 (59.5)
Antiplatelet agents     196 (19.1)
VKA    72 (7.0)
No anti-HT drugs  62 (6)
Monotherapy     366 (35.6)
2 drugs     366 (35.6)
3 or more anti-HT drugs     234 (22.7)
WBC: White blood cell; LVH: Left ventricle hypertrophy; HT: Hyperten-
sion; ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin 
receptor blocker; VKA: Vitamin K antagonist; LDL: Low-density lipopro-
tein. 
Table 2  Epidemiological, clinical and therapeutic differences 
between genders (mean ± SD)  n  (%)
Females Males P  value
(n  = 542) (n  = 486)
Mean age, yr 72.7 ± 5.8 72.8 ± 5.8 NS
Abdominal circumference, cm 96.6 ± 11.8 100.4 ± 11.0 < 0.001
Weight, kg 71.4 ± 11.5 79.5 ± 11.5 < 0.001
Mean height, cm 155.2 ± 6.7 166.7 ± 6.7 < 0.001
BMI 29.6 ± 4.5 28.6 ± 3.6 < 0.001
Obesity  224 (41.4)  160 (32.9) 0.005
Years from the onset of HT 11.0 ± 8.2 10.8 ± 8.1 NS
Diabetes mellitus  134 (24.7)  150 (30.9) 0.03
Dyslipidaemia  267 (49.3)  230 (47.3) NS
Smokers  17 (3.1)    76 (15.6) < 0.001
Sedentariness  352 (70.5)  274 (56.4) < 0.001
Regular alcohol intake    5 (0.9)  33 (6.8) < 0.001
History of stroke  32 (6.0)  32 (6.7) NS
History of IHD    55 (10.1)  124 (25.5) < 0.001
History of HF  35 (6.5)  39 (8.1) NS
History of renal insufficiency  24 (4.5)  38 (7.9) 0.025
Peripheral arterial disease  15 (2.7)  37 (7.7) 0.001
Carotid disease    2 (0.4)  13 (2.8) 0.003
Atrial fibrillation  50 (9.2)    56 (11.5) NS
CHADS ≥ 2  275 (50.7)  272 (56.0) NS
LVH by ECG  111 (20.5)    66 (13.6) 0.004
LVH_Sokolow    6 (1.1)    9 (1.9) NS
LVH_Cornell    91 (16.8)  12 (2.5) < 0.001
Mean HR, bpm 75.4 (10.7)  72.1(10.7) < 0.001
Mean number of anti-HT 1.7 ± 0.87 1.8 ± 1.0 NS
Diuretics  304 (56.1)  226 (46.5) 0.002
Beta-blockers  105 (19.4)    98 (20.2) NS
Calcium antagonists    93 (17.2)    80 (16.5) NS
ACEI  118 (21.8)  128 (26.3) NS
ARB  318 (58.7)  294 (60.5) NS
Antiplatelet agents    90 (16.6)  112 (23.0) 0.012
VKA  33 (6.1)  32 (6.6) NS
BMI: Body mass index; IHD: Ischaemic heart disease; HF: Heart failure; 
LVH: Left ventricle hypertrophy; HR: Heart rate; HT: Hypertension; ACEI: 
Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor 
blocker; VKA: Vitamin K antagonist. NS: No significant.
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95%CI: 0.68-0.81, and P < 0.01; and for the analysis of  
the women only, an area under the curve of  0.82, 95%CI: 
0.76-0.88, and P < 0.01). 
Treatment differences in patients with AF 
Regarding the treatment of  patients diagnosed with 
AF (Table 4), statistically significant differences were 
observed between the men and the women in their use 
of  calcium antagonists (8.9% vs 30%, respectively; P = 
0.007) and antiplatelet agents (26.8% vs 8%, respectively; 
P = 0.01). The rates of  use of  antiplatelet agents and 
anticoagulants was higher in the men than in the women, 
although this disparity was also not significant (71.4% vs 
66%, respectively; P = NS).
After stratification according to the CHADS2 cal-
culated score in patients with AF, we observed that the 
women and men had a similar rate of  using oral antico-
agulation therapy in all degrees of  CHADS2, except in 
CHADS2 = 2, in which the use of  anticoagulation ther-
apy in the women was nearly double the use in the men 
(Figure 1). 
DISCUSSION
This study is one of  the few in our country that analysed 
the prevalence of  AF[5] and epidemiological differences 
by gender in a hypertensive population of  over 65 years 
of  age visiting outpatient clinics. The AF prevalence de-
termined here (10.3%) is the same as the prevalence in 
another national registry, the CARDIOTENS 2009, which 
reported AF in 10.22% of  patients with cardiovascular 
disease or other risk factors and in 6.22% of  patients in 
the overall sample of  the registry[14]. These data are equal 
to twofold the prevalence reported in 1999[15], which did 
not include patients diagnosed “de novo” by ECG, and are 
slightly higher than the AF prevalence of  8.5% reported 
for the PREV-ICTUS registry, which analysed 7108 sub-
jects of  over 60 years of  age[16]. The higher AF prevalence 
reported in the current study is likely due to the different 
mean age of  the two study populations (72.8 years in the 
current study vs 71.9 years in the PREV-ICTUS study), 
the origin of  the recruited patients (here, primary care and 
hypertension units), and the method of  AF detection (here, 
presence in ECGs and history of  AF).
Furthermore, in our study, we noted gender differ-
ences between the classic epidemiological factors. Women 
exhibited a higher prevalence of  non-abdominal obesity, 
whereas men more frequently presented a history of  
diabetes; smoking; alcohol use; target-organ lesions; and 
established cardiovascular disease, such as ischaemic heart 
disease, peripheral arterial disease, and stroke. However, 
unlike in other studies[16], no significant differences were 
detected in the presence of  AF between men and women, 
although a slight disparity was noted (11.5% in men vs 9.2% 
in women).
Regarding the risk factors related to the presence of  
AF in women, the involvement of  the target organ, as in 
Table 3  Independent predictors of global atrial fibrillation 
in the total study population and in subgroups according to 
gender
Variable Total Females Males
OR (95%CI) OR (95%CI) OR (95%CI)
Age, yr 1.1 (1.1-1.1) 1.1 (1.1-1.1) 1.1 (1.03-1.13)
 P < 0.001 P = 0.010 P = 0.003
Alcohol abuse   5.2 (2.1-12.2) 7.0 (0.6-82.9) 4.2 (1.5-11.4)
P = 0.001 NS P = 0.005
Heart disease 4.7 (3.0-7.5) 6.1 (3.1-12.4), 3.4 (1.9-6.2)
 P < 0.001 P < 0.001 P < 0.01
GFR, mL/min per 
m2
  0.98 (0.97-0.99) 0.98 (0.96-0.99) 0.99 (0.9-1.0) 
P = 0.027 P = 0.039 NS
Strain on ECG 1.8 (0.9-3.4) 2.97 (1.1-8.1) 1.2 (0.53-2.81)
P = NS P = 0.032 NS
Multivariate analysis: Age, gender, body mass index, physical exercise, 
alcohol use, time from the onset of hypertension, clinical blood pressure, 
24-h ambulatory blood pressure monitoring result, family history of 
early cardiovascular disease, diabetes, smoking, obesity, dyslipidaemia, 
abdominal obesity, left ventricular hypertrophy, atherosclerotic plaque, 
renal damage, coronary disease, heart failure, renal disease, and treatment 
type. GFR: Glomerular filtration rate; ECG: Electrocardiogram; NS: No 
significant.
Table 4  Treatment differences between genders in patients 
with atrial fibrillation (n  = 106)  n  (%)
Females Males P  value
(n  = 50) (n  = 56)
Diuretics    34 (68.0)    30 (53.6) NS
Beta-blockers 16 (32)    17 (30.4) NS
Calcium antagonists 15 (30)    5 (8.9) 0.007
ACEI 12 (24) 14 (25) NS
ARB 32 (64)    31 (55.4) NS
Antiplatelet agents 4 (8)    16 (26.8) 0.010
VKA 29 (58)    25 (44.6) NS
ATG or VKA 33 (66)    41 (71.4) NS
ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin 
receptor blocker; VKA: Vitamin K antagonist; ATG: Anti-aggregants. NS: 
No significant. 
100
80
60
40
20
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%
Men
Women
CHADS1          CHADS2          CHADS3       CHADS > 3
Number of patients:
Women          10                 13                16                   6
Men               18                 16                16                   6
Figure 1  Gender differences in the use of anticoagulation therapy be-
tween groups according to CHADS2 score. 
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the cases of  LVH and renal dysfunction, and heart disease 
are significant conditions associated with this arrhythmia. 
In contrast, in men, excessive alcohol intake has a strong 
association with this condition, possibly due to the toxic 
effect of  alcohol on the myocardium[17]. This knowledge 
can help clinicians to develop strategies to prevent AF in 
the hypertensive population. In women, our effort should 
be aimed at a greater control of  BP to prevent the occur-
rence of  lesions in target organs and of  cardiovascular 
disease, whereas in men, the reduction of  alcohol intake 
should be an additional objective, as described in other 
recent studies[18,19]. 
Moreover, an important finding of  our study is the 
treatment differences between genders in patients with 
AF, and particularly differences in the use of  antiplatelet 
agents and anticoagulants. Although the data were is not 
significant, we observed greater use in men, in contrast 
to the results obtained by Riesgo et al[20], who reported 
more frequent use in women. However, the patient pro-
file of  this prior study was different, as the subjects were 
recruited only from primary care, and the results were 
also not significant. Our results are similar to the findings 
of  another recent report indicating higher rates of  anti-
coagulation therapy use in men but no significant gender-
related differences for other treatments[21]. Yet, when the 
population was stratified into groups based on CHADS2 
score, women with a score of  2 had a nearly twofold 
higher rate of  using oral anticoagulants than men. One 
potential reason for this discrepancy is the perception 
that women have a higher incidence of  stroke as a com-
plication of  the evolution of  AF[22,23]. This perception 
could lead to the expectation that women receive anti-ag-
gregation and anticoagulation more frequently than men, 
as recommended in the most recent practice guidelines 
published[24], in which the female gender is assigned one 
point on the new CHADS2-VAS2C scale. Thus, hypothet-
ically, if  the practice guidelines were applied to this study, 
the rate of  anticoagulant use in women should approach 
100% if  there is no contraindication (the CHADS2-
VAS2C score in the women included in this study was 3). 
One of  the main limitations of  this sub-study is that it 
was not specifically designed to analyse differences be-
tween genders. Additionally, the sub-study did not analyse 
the initial reason for a consultation to diagnose arrhyth-
mia, which would have contributed to a better interpre-
tation of  the results. There also may be other unknown 
confounding factors related to practitioner preferences 
and guideline adherence, which could explain the pres-
ence or absence of  gender-related differences. Finally, the 
nonrandomised selection of  physicians and patients may 
reduce the external validity of  the study.
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Background
The incidence of atrial fibrillation (AF) is important in the general population but 
is even more so in hypertensive patients. As atrial fibrillation increases cardio-
vascular risk, knowledge of the factors that are associated with this condition 
is highly clinically relevant. Furthermore, the incidence of atrial fibrillation in 
women is different than in men, and therefore, the factors associated with atrial 
fibrillation in women may also be different.
Research frontiers
Risk factors related to the presence of atrial fibrillation are under investigation, 
as knowledge of these factors can aid the development of preventive strategies. 
The difference in risk between men and women is also being studied in the field 
of cardiovascular medicine.
Innovations and breakthroughs
It is possible that the more aggressive treatment of these patients, particularly 
by administering cardiovascular drugs, could improve the patients’ prognosis.
Applications
The main application of this registry is to determine the risk factors associated 
with atrial fibrillation. By targeting these factors, we can avoid the development 
of this disease in both men and women, which has been little studied in large 
clinical trials.
Terminology
AF is the most common cardiac arrhythmia (irregular heart beat). It may cause 
no symptoms, but it is often associated with palpitations, fainting, chest pain, or 
Fácila L et al . Gender differences
 COMMENTS
130 May 26, 2013|Volume 5|Issue 5|WJC|www.wjgnet.com
congestive heart failure. However, in some people atrial fibrillation is caused by 
otherwise idiopathic or benign conditions. Hypertension or high blood pressure, 
arterial hypertension, is a chronic medical condition in which the blood pres-
sure in the arteries is elevated. ROC curve, is a graphical plot which illustrates 
the performance of a binary classifier system as its discrimination threshold is 
varied. It is created by plotting the fraction of true positives out of the positives 
true positive rate (TPR) vs the fraction of false positives out of the negatives 
false positive rate (FPR), at various threshold settings. TPR is also known as 
sensitivity (also called recall in some fields), and FPR is one minus the specific-
ity or true negative rate. Univariate analysis is the simplest form of quantitative 
(statistical) analysis. The analysis is carried out with the description of a single 
variable and its attributes of the applicable unit of analysis. For example, if the 
variable age was the subject of the analysis, the researcher would look at how 
many subjects fall into a given age attribute categories.
Peer review
This study is one of the few in our country that analyses the prevalence of AF and 
the epidemiological differences by gender in a hypertensive population of over 65 
years of age attended in outpatient clinics. 
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